The spectrum of oculocutaneous disease : Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease - 16/04/14

Doi : 10.1016/j.jaad.2013.12.013

Mary E. Horner, MD ^a, Amanda K. Abramson, MD ^a, Richard B. Warren, MD ^b, Susan Swanson, MD ^c, M. Alan Menter, MD ^a,^⁎
^a Baylor University Medical Center, Dallas, Texas
^c Private practice, Dallas, Texas
^b The Dermatology Centre, Salford Royal National Health Service Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

^∗Reprint requests: M. Alan Menter, MD, Baylor University Medical Center, Texas A&M Health Science Center, 3900 Junius St, Ste 125, Dallas, TX 75246.

Abstract

Many skin diseases are associated with ocular findings, emphasizing the need for dermatologists to be fully aware of their presence, and as a result, avoid overlooking conditions with potentially major ocular complications, including blindness. We review important oculocutaneous disease associations with recommendations for the management of the ocular complications and appropriate referral to our ophthalmology colleagues. Part I of this 2-part review focuses on the infectious, inflammatory, and genetic relationships.

Le texte complet de cet article est disponible en PDF.

Key words : autoimmune, dermatology, genetic, infection, inflammatory, oculocutaneous, ophthalmology

Plan

Connective tissue diseases

Miscellaneous

Genodermatoses

Associated with pigment abnormalities

Disorders of keratinization

Neoplasm associations

Miscellaneous

Conclusion

Funding sources: None.

Dr Alan Menter has reported the following financial relationships: Abbott Laboratories, Consultant, Honorarium; Abbott Laboratories, Speaker, Honorarium; Abbott Laboratories, Principle Investigator, Honorarium; Abbott Laboratories, Advisory Board, Grants/Research Funding; AbbVie, Speaker, Fees; Amgen, Advisory Board, Grants/Research Funding; Amgen, Speaker, Honorarium; Astellas Pharma US, Inc, Advisory Board, Honorarium; Astellas Pharma US, Inc, Consultant, Grants/Research Funding; Celgene Corporation, Principal Investigator, Grants/Research Funding; Centocor Ortho Biotech, Inc, Consultant, Grants/Research Funding; Centocor Ortho Biotech, Inc, Advisory Board, Honorarium; Eli Lilly and Company, Principal Investigator, Grants/Research Funding; Galderma Laboratories, Advisory Board, Honorarium; Galderma Laboratories, Speaker, Honorarium; Genentech, Inc, Advisory Board, Grants/Research Funding; Novartis Pharmaceuticals Corp, Principal Investigator, Grants/Research Funding; Novo Nordisk A/S, Principal Investigator, Grants/Research Funding; Pfizer, Inc, Speaker, Honorarium; Pfizer, Inc, Advisory Board, Honorarium; Pfizer, Inc, Principal Investigator, Grants/Research Funding; Promius Pharma, LLC, Principal Investigator, Grants/Research Funding; Stiefel a GSK company, Principal Investigator, Grants/Research Funding; Syntrix, Principal Investigator, Grants/Research Funding; Warner Chilcott, Advisory Board, Honorarium; Warner Chilcott, Advisory Board, Honorarium. Dr Richard B. Warren has reported the following financial relationships: Abbvie, Advisory Board, Honorarium; AbbVie, Speaker, Honorarium; Amgen, Consultant, Honorarium; Leo, Advisory Board, Honorarium; Leo, Speaker, Honorarium; Pfizer, Inc, Advisory Board, Honorarium; Pfizer, Inc, Speaker, Honorarium; Novartis Pharmaceuticals Corp, Advisory Board, Honorarium; Novartis Pharmaceuticals Corp, Speaker, Honorarium; Novartis Pharmaceuticals Corp, Principal Investigator, Honorarium; Janssen, Advisory Board, Honorarium; Janssen, Speaker, Honorarium. Drs Amanda Abramson, Mary E. Horner and Susan Swanson have no conflicts of interest to disclose.